Presidio Pharmaceuticals Completes Phase I Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients With Genotype-1 Infection

Presidio Pharmaceuticals announced successful completion of Phase Ib clinical testing of its lead HCV NS5A inhibitor in patients with HCV genotype-1 infection, with positive efficacy and safety observations supporting advancement of PPI-668 to Phase II combination studies.
Enhanced Online News